HIV-1 Rev multimerization: Mechanism and insights

Current HIV Research

Volumn 11, Issue 8, 2013, Pages 623-634

  Vercruysse, Thomas ^a   Daelemans, Dirk ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Co operative interactions; HIV 1; Multimerization; Protein protein interactions; Protein RNA interactions; Rev; RNA export; Viral replication control

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; NUCLEOPHOSMIN; REV PROTEIN; CELL RECEPTOR; EXPORTIN 1 PROTEIN; KARYOPHERIN; MESSENGER RNA; VIRUS RNA;

ANTIVIRAL THERAPY; BINDING AFFINITY; CRYSTALLIZATION; GENE EXPRESSION; GENE MUTATION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN MULTIMERIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; REVIEW; RNA METABOLISM; STOICHIOMETRY; CELL NUCLEUS; CYTOPLASM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CELL NUCLEUS; CYTOPLASM; GENE EXPRESSION REGULATION, VIRAL; HIV-1; HUMANS; KARYOPHERINS; PROTEIN MULTIMERIZATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, MESSENGER; RNA, VIRAL;

EID: 84900489279     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X12666140307094603     Document Type: Review

References (153)

1. Freed EO. HIV-1 replication. Somat Cell Mol Genet 2001; 26(1-6): 13-33.
2. Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol 1998; 52: 491-532.
3. Stoltzfus CM, Madsen JM. Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing. Curr HIV Res 2006; 4(1): 43-55.
4. Cullen BR. Nuclear RNA export. J Cell Sci 2003; 116(4): 587-97.
5. Nakielny S, Fischer U, Michael WM, Dreyfuss G. RNA transport. Annu Rev Neurosci 1997; 20: 269-301.
6. Cullen BR. Retroviruses as model systems for the study of nuclear RNA export pathways. Virology 1998; 249(2): 203-10.
7. Hope TJ. The ins and outs of HIV Rev. Arch Biochem Biophys 1999; 365(2): 186-91.
8. Malim MH, Cullen BR. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 1991; 65(2): 241-8.
9. Cole JL, Gehman JD, Shafer JA, Kuo LC. Solution oligomerization of the rev protein of HIV-1: implications for function. Biochemistry 1993; 32(44): 11769-75.
10. Wingfield PT, Stahl SJ, Payton MA, Venkatesan S, Misra M, Steven AC. HIV-1 Rev expressed in recombinant Escherichia coli: purification, polymerization, and conformational properties. Biochemistry 1991; 30(30): 7527-34.
11. Zapp ML, Hope TJ, Parslow TG, Green MR. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc Natl Acad Sci USA 1991; 88(17): 7734-8.
12. Heaphy S, Finch JT, Gait MJ, Karn J, Singh M. Human immunodeficiency virus type 1 regulator of virion expression, rev, forms nucleoprotein filaments after binding to a purine-rich bubble located within the rev-responsive region of viral mRNAs. Proc Natl Acad Sci USA 1991; 88(16): 7366-70.
13. Watts NR, Misra M, Wingfield PT, et al. Three-dimensional structure of HIV-1 Rev protein filaments. J Struct Biol 1998; 121(1): 41-52.
14. Havlin RH, Blanco FJ, Tycko R. Constraints on protein structure in HIV-1 Rev and Rev-RNA supramolecular assemblies from twodimensional solid state nuclear magnetic resonance. Biochemistry 2007; 46(11): 3586-93.
15. Daugherty MD, Booth DS, Jayaraman B, Cheng Y, Frankel AD. HIV Rev response element (RRE) directs assembly of the Rev homooligomer into discrete asymmetric complexes. Proc Natl Acad Sci USA 2010; 107(28): 12481-6.
16. Marenchino M, Armbruster DW, Hennig M. Rapid and efficient purification of RNA-binding proteins: application to HIV-1 Rev. Protein Expr Purif 2009; 63(2): 112-9.
17. Daugherty MD, Liu B, Frankel AD. Structural basis for cooperative RNA binding and export complex assembly by HIV Rev. Nat Struct Mol Biol 2010; 17(11): 1337-42.
18. Dayton ET, Powell DM, Dayton AI. Functional analysis of CAR, the target sequence for the Rev protein of HIV-1. Science 1989; 246(4937): 1625-9.
19. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989; 338(6212): 254-7.
20. Huang XJ, Hope TJ, Bond BL, McDonald D, Grahl K, Parslow TG. Minimal Rev-response element for type 1 human immunodeficiency virus. J Virol 1991; 65(4): 2131-4.
21. Holland SM, Ahmad N, Maitra RK, Wingfield P, Venkatesan S. Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure. J Virol 1990; 64(12): 5966-75.
22. Cook KS, Fisk GJ, Hauber J, Usman N, Daly TJ, Rusche JR. Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate. Nucleic Acids Res 1991; 19(7): 1577-83.
23. Pond SJ, Ridgeway WK, Robertson R, Wang J, Millar DP. HIV-1 Rev protein assembles on viral RNA one molecule at a time. Proc Natl Acad Sci USA 2009; 106(5): 1404-8.
24. Malim MH, Tiley LS, McCarn DF, Rusche JR, Hauber J, Cullen BR. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 1990; 60(4): 675-83.
25. Tiley LS, Malim MH, Tewary HK, Stockley PG, Cullen BR. Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. Proc Natl Acad Sci USA 1992; 89(2): 758-62.
26. Olsen HS, Nelbock P, Cochrane AW, Rosen CA. Secondary structure is the major determinant for interaction of HIV rev protein with RNA. Science 1990; 247(4944): 845-8.
27. Iwai S, Pritchard C, Mann DA, Karn J, Gait MJ. Recognition of the high affinity binding site in rev-response element RNA by the human immunodeficiency virus type-1 Rev protein. Nucleic Acids Res 1992; 20(24): 6465-72.
28. Bartel DP, Zapp ML, Green MR, Szostak JW. HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell 1991; 67(3): 529-36.
29. Battiste JL, Tan R, Frankel AD, Williamson JR. Binding of an HIV Rev peptide to Rev responsive element RNA induces formation of purine-purine base pairs. Biochemistry 1994; 33(10): 2741-7.
30. Battiste JL, Mao H, Rao NS, et al. Alpha helix-RNA major groove recognition in an HIV-1 rev peptide-RRE RNA complex. Science 1996; 273(5281): 1547-51.
31. Williamson JR, Battiste JL, Mao H, Frankel AD. Interaction of HIV Rev peptides with the Rev response element RNA. Nucleic Acids Symp Ser 1995(33): 46-8.
32. Peterson RD, Bartel DP, Szostak JW, Horvath SJ, Feigon J. 1H NMR studies of the high-affinity Rev binding site of the Rev responsive element of HIV-1 mRNA: base pairing in the core binding element. Biochemistry 1994; 33(18): 5357-66.
33. Peterson RD, Feigon J. Structural change in Rev responsive element RNA of HIV-1 on binding Rev peptide. J Mol Biol 1996; 264(5): 863-77.
34. Hung LW, Holbrook EL, Holbrook SR. The crystal structure of the Rev binding element of HIV-1 reveals novel base pairing and conformational variability. Proc Natl Acad Sci USA 2000; 97(10): 5107-12.
35. Ippolito JA, Steitz TA. The structure of the HIV-1 RRE high affinity rev binding site at 1.6 A resolution. J Mol Biol 2000; 295(4): 711-7.
36. Tan R, Chen L, Buettner JA, Hudson D, Frankel AD. RNA recognition by an isolated alpha helix. Cell 1993; 73(5): 1031-40.
37. Ye X, Gorin A, Ellington AD, Patel DJ. Deep penetration of an alpha-helix into a widened RNA major groove in the HIV-1 rev peptide-RNA aptamer complex. Nat Struct Biol 1996; 3(12): 1026-33.
38. Tan R, Frankel AD. Costabilization of peptide and RNA structure in an HIV Rev peptide-RRE complex. Biochemistry 1994; 33(48): 14579-85.
39. Daugherty MD, D'Orso I, Frankel AD. A solution to limited genomic capacity: using adaptable binding surfaces to assemble the functional HIV Rev oligomer on RNA. Mol Cell 2008; 31(6): 824-34.
40. Dayton ET, Konings DA, Powell DM, et al. Extensive sequencespecific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein. J Virol 1992; 66(2): 1139-51.
41. Dillon PJ, Nelbock P, Perkins A, Rosen CA. Function of the human immunodeficiency virus types 1 and 2 Rev proteins is dependent on their ability to interact with a structured region present in env gene mRNA. J Virol 1990; 64(9): 4428-37.
42. Fenster SD, Wagner RW, Froehler BC, Chin DJ. Inhibition of human immunodeficiency virus type-1 env expression by C-5 propyne oligonucleotides specific for Rev-response element stemloop V. Biochemistry 1994; 33(28): 8391-8.
43. Possik EJ, Bou Sleiman MS, Ghattas IR, Smith CA. Randomized codon mutagenesis reveals that the HIV Rev arginine-rich motif is robust to substitutions and that double substitution of two critical residues alters specificity. Journal of molecular recognition: J Mol Recognit 2013; 26(6): 286-96.
44. Gallego J, Greatorex J, Zhang H, et al. Rev binds specifically to a purine loop in the SL1 region of the HIV-1 leader RNA. J Biol Chem 2003; 278(41): 40385-91.
45. Groom HC, Anderson EC, Dangerfield JA, Lever AM. Rev regulates translation of human immunodeficiency virus type-1 RNAs. J Gen Virol 2009; 90(Pt 5): 1141-7.
46. Grewe B, Ehrhardt K, Hoffmann B, Blissenbach M, Brandt S, Uberla K. The HIV-1 Rev protein enhances encapsidation of Unspliced and spliced, RRE-containing lentiviral vector RNA. PloS one 2012; 7(11): e48688.
47. Cockrell AS, van Praag H, Santistevan N, Ma H, Kafri T. The HIV-1 Rev/RRE system is required for HIV-1 5' UTR cis elements to augment encapsidation of heterologous RNA into HIV-1 viral particles. Retrovirology 2011; 8: 51.
48. Xu W, Ellington AD. Anti-peptide aptamers recognize amino acid sequence and bind a protein epitope. Proc Natl Acad Sci USA 1996; 93(15): 7475-80.
49. Smith CA, Calabro V, Frankel AD. An RNA-binding chameleon. Mol Cell 2000; 6(5): 1067-76.
50. Bayer TS, Booth LN, Knudsen SM, Ellington AD. Arginine-rich motifs present multiple interfaces for specific binding by RNA. RNA 2005; 11(12): 1848-57.
51. Casu F, Duggan BM, Hennig M. The arginine-rich RNA-binding motif of HIV-1 Rev is intrinsically disordered and folds upon RRE binding. Biophys J 2013; 105(4): 1004-17.
52. Berger J, Aepinus C, Dobrovnik M, Fleckenstein B, Hauber J, Bohnlein E. Mutational analysis of functional domains in the HIV-1 Rev trans-regulatory protein. Virology 1991; 183(2): 630-5.
53. Kjems J, Calnan BJ, Frankel AD, Sharp PA. Specific binding of a basic peptide from HIV-1 Rev. EMBO J 1992; 11(3): 1119-29.
54. Madore SJ, Tiley LS, Malim MH, Cullen BR. Sequence requirements for Rev multimerization in vivo. Virology 1994; 202(1): 186-94.
55. Szilvay AM, Brokstad KA, Boe SO, Haukenes G, Kalland KH. Oligomerization of HIV-1 Rev mutants in the cytoplasm and during nuclear import. Virology 1997; 235(1): 73-81.
56. Olsen HS, Cochrane AW, Dillon PJ, Nalin CM, Rosen CA. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids. Genes Dev 1990; 4(8): 1357-64.
57. Malim MH, Bohnlein S, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator-derivation of a transdominant repressor of Rev function. Cell 1989; 58(1): 205-14.
58. Thomas SL, Oft M, Jaksche H, et al. Functional analysis of the human immunodeficiency virus type 1 Rev protein oligomerization interface. J Virol 1998; 72(4): 2935-44.
59. Bogerd H, Greene WC. Dominant negative mutants of human Tcell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo. J Virol 1993; 67(5): 2496-502.
60. Brice PC, Kelley AC, Butler PJ. Sensitive in vitro analysis of HIV-1 Rev multimerization. Nucleic Acids Res 1999; 27(10): 2080-5.
61. Daly TJ, Doten RC, Rusche JR, Auer M. The amino terminal domain of HIV-1 Rev is required for discrimination of the RRE from nonspecific RNA. J Mol Biol 1995; 253(2): 243-58.
62. Charpentier B, Stutz F, Rosbash M. A dynamic in vivo view of the HIV-I Rev-RRE interaction. J Mol Biol 1997; 266(5): 950-62.
63. Daly TJ, Rusche JR, Maione TE, Frankel AD. Circular dichroism studies of the HIV-1 Rev protein and its specific RNA binding site. Biochemistry 1990; 29(42): 9791-5.
64. Blanco FJ, Hess S, Pannell LK, Rizzo NW, Tycko R. Solid-state NMR data support a helix-loop-helix structural model for the Nterminal half of HIV-1 Rev in fibrillar form. J Mol Biol 2001; 313(4): 845-59.
65. Auer M, Gremlich HU, Seifert JM, et al. Helix-loop-helix motif in HIV-1 Rev. Biochemistry 1994; 33(10): 2988-96.
66. Jensen TH, Jensen A, Szilvay AM, Kjems J. Probing the structure of HIV-1 Rev by protein footprinting of multiple monoclonal antibody-binding sites. FEBS Lett 1997; 414(1): 50-4.
67. Soman KV, Braun W. Determining the three-dimensional fold of a protein from approximate constraints: a simulation study. Cell Biochem Biophys 2001; 34(3): 283-304.
68. Jain C, Belasco JG. Structural model for the cooperative assembly of HIV-1 Rev multimers on the RRE as deduced from analysis of assembly-defective mutants. Mol Cell 2001; 7(3): 603-14.
69. DiMattia MA, Watts NR, Stahl SJ, et al. Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element. Proc Natl Acad Sci USA 2010; 107(13): 5810-4.
70. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D. An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production. J Biol Chem 2010; 285(28): 21768-80.
71. Venken T, Daelemans D, de Maeyer M, Voet A. Computational investigation of the HIV-1 Rev multimerization using molecular dynamics simulations and binding free energy calculations. Proteins 2012; 80(6): 1633-46.
72. Edgcomb SP, Aschrafi A, Kompfner E, Williamson JR, Gerace L, Hennig M. Protein structure and oligomerization are important for the formation of export-competent HIV-1 Rev-RRE complexes. Protein Sci 2008; 17(3): 420-30.
73. Trikha R, Brighty DW. Phenotypic analysis of human immunodeficiency virus type-1 Rev trimerization-interface mutants in human cells. J Gen Virol 2005; 86(Pt 5): 1509-13.
74. Mann DA, Mikaelian I, Zemmel RW, et al. A molecular rheostat. Co-operative rev binding to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression. J Mol Biol 1994; 241(2): 193-207.
75. Zemmel RW, Kelley AC, Karn J, Butler PJ. Flexible regions of RNA structure facilitate co-operative Rev assembly on the Revresponse element. J Mol Biol 1996; 258(5): 763-77.
76. Kjems J, Sharp PA. The basic domain of Rev from human immunodeficiency virus type 1 specifically blocks the entry of U4/U6.U5 small nuclear ribonucleoprotein in spliceosome assembly. J Virol 1993; 67(8): 4769-76.
77. Fang X, Wang J, O'Carroll IP, et al. An unusual topological structure of the HIV-1 Rev response element. Cell 2013; 155(3): 594-605.
78. Legiewicz M, Badorrek CS, Turner KB, et al. Resistance to RevM10 inhibition reflects a conformational switch in the HIV-1 Rev response element. Proc Natl Acad Sci USA 2008; 105(38): 14365-70.
79. Shuck-Lee D, Chang H, Sloan EA, Hammarskjold ML, Rekosh D. Single-nucleotide changes in the HIV Rev-response element mediate resistance to compounds that inhibit Rev function. J Virol 2011; 85(8): 3940-9.
80. Daly TJ, Cook KS, Gray GS, Maione TE, Rusche JR. Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature 1989; 342(6251): 816-9.
81. Daly TJ, Doten RC, Rennert P, et al. Biochemical characterization of binding of multiple HIV-1 Rev monomeric proteins to the Rev responsive element. Biochemistry 1993; 32(39): 10497-505.
82. Pallesen J, Dong M, Besenbacher F, Kjems J. Structure of the HIV-1 Rev response element alone and in complex with regulator of virion (Rev) studied by atomic force microscopy. FEBS J 2009; 276(15): 4223-32.
83. van Ryk DI, Venkatesan S. Real-time kinetics of HIV-1 Rev-Rev response element interactions. Definition of minimal binding sites on RNA and protein and stoichiometric analysis. J Biol Chem 1999; 274(25): 17452-63.
84. Jeong KS, Nam YS, Venkatesan S. Deletions near the N-terminus of HIV-1 Rev reduce RNA binding affinity and dominantly interfere with Rev function irrespective of the RNA target. Arch Virol 2000; 145(12): 2443-67.
85. Holland SM, Chavez M, Gerstberger S, Venkatesan S. A specific sequence with a bulged guanosine residue(s) in a stem-bulge-stem structure of Rev-responsive element RNA is required for trans activation by human immunodeficiency virus type 1 Rev. J Virol 1992; 66(6): 3699-706.
86. Thomas SL, Hauber J, Casari G. Probing the structure of the HIV-1 Rev trans-activator protein by functional analysis. Protein Eng 1997; 10(2): 103-7.
87. Hoffmann D, Schwarck D, Banning C, et al. Formation of Trans-Activation Competent HIV-1 Rev: RRE Complexes Requires the Recruitment of Multiple Protein Activation Domains. PloS One 2012; 7(6): e38305.
88. Daly TJ, Rennert P, Lynch P, et al. Perturbation of the carboxy terminus of HIV-1 Rev affects multimerization on the Rev responsive element. Biochemistry 1993; 32(34): 8945-54.
89. Stauber RH, Afonina E, Gulnik S, Erickson J, Pavlakis GN. Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells. Virology 1998; 251(1): 38-48.
90. Daelemans D, Costes SV, Cho EH, Erwin-Cohen RA, Lockett S, Pavlakis GN. In vivo HIV-1 Rev multimerization in the nucleolus and cytoplasm identified by fluorescence resonance energy transfer. J Biol Chem 2004; 279(48): 50167-75.
91. Banning C, Votteler J, Hoffmann D, et al. A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PloS One 2010; 5(2): e9344.
92. Daelemans D, Afonina E, Nilsson J, et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci USA 2002; 99(22): 14440-5.
93. Furnes C, Andresen V, Szilvay AM. Functional rescue of an oligomerization-defective HIV-1 Rev mutant by fusion with an oligomeric tag. Arch Virol 2008; 153(2): 357-62.
94. Szilvay AM, Brokstad KA, Kopperud R, Haukenes G, Kalland KH. Nuclear export of the human immunodeficiency virus type 1 nucleocytoplasmic shuttle protein Rev is mediated by its activation domain and is blocked by transdominant negative mutants. J Virol 1995; 69(6): 3315-23.
95. Stauber R, Gaitanaris GA, Pavlakis GN. Analysis of trafficking of Rev and transdominant Rev proteins in living cells using green fluorescent protein fusions: transdominant Rev blocks the export of Rev from the nucleus to the cytoplasm. Virology 1995; 213(2): 439-49.
96. Rocak S, Linder P. DEAD-box proteins: the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol 2004; 5(3): 232-41.
97. Cordin O, Banroques J, Tanner NK, Linder P. The DEAD-box protein family of RNA helicases. Gene 2006; 367: 17-37.
98. Yasuda-Inoue M, Kuroki M, Ariumi Y. Distinct DDX DEAD-box RNA helicases cooperate to modulate the HIV-1 Rev function. Biochem Biophys Res Commun 2013; 434(4): 803-8.
99. Krishnan V, Zeichner SL. Alterations in the expression of DEADbox and other RNA binding proteins during HIV-1 replication. Retrovirology 2004; 1: 42.
100. Fang J, Kubota S, Yang B, et al. A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. Virology 2004; 330(2): 471-80.
101. Yedavalli VS, Neuveut C, Chi YH, Kleiman L, Jeang KT. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 2004; 119(3): 381-92.
102. Ma J, Rong L, Zhou Y, et al. The requirement of the DEAD-box protein DDX24 for the packaging of human immunodeficiency virus type-1 RNA. Virology 2008; 375(1): 253-64.
103. Neumann M, Felber BK, Kleinschmidt A, et al. Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function. J Virol 1995; 69(4): 2159-67.
104. Ludwig E, Silberstein FC, van Empel J, Erfle V, Neumann M, Brack-Werner R. Diminished rev-mediated stimulation of human immunodeficiency virus type 1 protein synthesis is a hallmark of human astrocytes. J Virol 1999; 73(10): 8279-89.
105. Fang J, Acheampong E, Dave R, Wang F, Mukhtar M, Pomerantz RJ. The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes. Virology 2005; 336(2): 299-307.
106. Haukenes G, Szilvay AM, Brokstad KA, Kanestrom A, Kalland KH. Labeling of RNA transcripts of eukaryotic cells in culture with BrUTP using a liposome transfection reagent (DOTAP). Biotechniques 1997; 22(2): 308-12.
107. Edgcomb SP, Carmel AB, Naji S, et al. DDX1 is an RNAdependent ATPase involved in HIV-1 Rev function and virus replication. J Mol Biol 2012; 415(1): 61-74.
108. Robertson-Anderson RM, Wang J, Edgcomb SP, Carmel AB, Williamson JR, Millar DP. Single-molecule studies reveal that DEAD box protein DDX1 promotes oligomerization of HIV-1 Rev on the Rev response element. J Mol Biol 2011; 410(5): 959-71.
109. Hadian K, Vincendeau M, Mausbacher N, et al. Identification of a heterogeneous nuclear ribonucleoprotein-recognition region in the HIV Rev protein. J Biol Chem 2009; 284(48): 33384-91.
110. Okuwaki M. The structure and functions of NPM1/Nucleophsmin/ B23, a multifunctional nucleolar acidic protein. J Biochem 2008; 143(4): 441-8.
111. Ye K. Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis. Cancer Biol Ther 2005; 4(9): 918-23.
112. Yung BY. Oncogenic role of nucleophosmin/B23. Chang Gung Med J 2007; 30(4): 285-93.
113. Lim MJ, Wang XW. Nucleophosmin and human cancer. Cancer Detect Prev 2006; 30(6): 481-90.
114. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6(7): 493-505.
115. Fankhauser C, Izaurralde E, Adachi Y, Wingfield P, Laemmli UK. Specific complex of human immunodeficiency virus type-1 rev and nucleolar B23 proteins: dissociation by the Rev response element. Mol Cell Biol 1991; 11(5): 2567-75.
116. Szebeni A, Mehrotra B, Baumann A, Adam SA, Wingfield PT, Olson MO. Nucleolar protein B23 stimulates nuclear import of the HIV-1 Rev protein and NLS-conjugated albumin. Biochemistry 1997; 36(13): 3941-9.
117. Szebeni A, Olson MO. Nucleolar protein B23 has molecular chaperone activities. Protein Sci 1999; 8(4): 905-12.
118. Neville M, Stutz F, Lee L, Davis LI, Rosbash M. The import inbeta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr Biol 1997; 7(10): 767-75.
119. Meyer BE, Malim MH. The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev 1994; 8(13): 1538-47.
120. Hakata Y, Yamada M, Mabuchi N, Shida H. The carboxy-terminal region of the human immunodeficiency virus type 1 protein Rev has multiple roles in mediating CRM1-related Rev functions. J Virol 2002; 76(16): 8079-89.
121. Kimura T, Ohyama A. Interaction with the Rev response element along an extended stem I duplex structure is required to complete human immunodeficiency virus type 1 rev-mediated transactivation in vivo. J Biochem 1994; 115(5): 945-52.
122. Surendran R, Herman P, Cheng Z, Daly TJ, Ching Lee J. HIV Rev self-assembly is linked to a molten-globule to compact structural transition. Biophys Chem 2004; 108(1-3): 101-19.
123. Pomerantz RJ, Seshamma T, Trono D. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol 1992; 66(3): 1809-13.
124. Kim SY, Byrn R, Groopman J, Baltimore D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 1989; 63(9): 3708-13.
125. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 1990; 61(7): 1271-6.
126. Sloan EA, Kearney MF, Gray LR, et al. Limited nucleotide changes in the Rev response element (RRE) during HIV-1 infection alter overall Rev-RRE activity and Rev multimerization. J Virol 2013; 87(20): 11173-86.
127. Iversen AK, Shpaer EG, Rodrigo AG, et al. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol 1995; 69(9): 5743-53.
128. Bobbitt KR, Addo MM, Altfeld M, et al. Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing. Immunity 2003; 18(2): 289-99.
129. Papathanasopoulos MA, Patience T, Meyers TM, McCutchan FE, Morris L. Full-length genome characterization of HIV type 1 subtype C isolates from two slow-progressing perinatally infected siblings in South Africa. AIDS Res Hum Retroviruses 2003; 19(11): 1033-7.
130. Hope TJ, Klein NP, Elder ME, Parslow TG. trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes. J Virol 1992; 66(4): 1849-55.
131. Askjaer P, Bachi A, Wilm M, et al. RanGTP-regulated interactions of CRM1 with nucleoporins and a shuttling DEAD-box helicase. Mol Cell Biol 1999; 19(9): 6276-85.
132. Guzik BW, Levesque L, Prasad S, et al. NXT1 (p15) is a crucial cellular cofactor in TAP-dependent export of intron-containing RNA in mammalian cells. Mol Cell Biol 2001; 21(7): 2545-54.
133. Furnes C, Arnesen T, Askjaer P, Kjems J, Szilvay AM. HIV-1 Rev oligomerization is not obligatory in the presence of an extra basic domain. Retrovirology 2005; 2: 39.
134. Groom HC, Anderson EC, Lever AM. Rev: beyond nuclear export. J Gen Virol 2009; 90(Pt 6): 1303-18.
135. McLaren M, Marsh K, Cochrane A. Modulating HIV-1 RNA processing and utilization. Front Biosci 2008; 13: 5693-707.
136. Suhasini M, Reddy TR. Cellular proteins and HIV-1 Rev function. Curr HIV Res 2009; 7(1): 91-100.
137. Liu J, Henao-Mejia J, Liu H, Zhao Y, He JJ. Translational regulation of HIV-1 replication by HIV-1 Rev cellular cofactors Sam68, eIF5A, hRIP, and DDX3. J Neuroimmune Pharmacol 2011; 6(2): 308-21.
138. Grewe B, Uberla K. The human immunodeficiency virus type 1 Rev protein: menage a trois during the early phase of the lentiviral replication cycle. J Gen Virol 2010; 91(Pt 8): 1893-7.
139. Daelemans D, Pannecouque C. HIV-1 Rev function as target for antiretroviral drug development. Curr Opin HIV AIDS 2006; 1(5): 388-97.
140. Wolff B, Sanglier JJ, Wang Y. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 1997; 4(2): 139-47.
141. Roisin A, Robin JP, Dereuddre-Bosquet N, et al. Inhibition of HIV-1 replication by cell-penetrating peptides binding Rev. J Biol Chem 2004; 279(10): 9208-14.
142. van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 2008; 16(21): 9487-97.
143. Vercruysse T, Pawar S, de Borggraeve W, et al. Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer. RNA Biol 2011; 8(2): 316-24.
144. Vercruysse T, Boons E, Venken T, et al. Mapping the binding interface between an HIV-1 inhibiting intrabody and the viral protein Rev. PloS One 2013; 8(4): e60259.
145. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007; 77(1): 13-22.
146. Ablynx. Ablynx' product portfolio 2012. Available from: http://www.ablynx.com.
147. Lipinski CA, Lombardo F, Dominy BW, Feeny PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1997; 23: 3-25.
148. Zinzalla G, Thurston DE. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med Chem 2009; 1(1): 65-93.
149. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angewandte Chemie-International Edition 2005; 44(27): 4130-63.
150. Chene P. Drugs targeting protein-protein interactions. Chem Med Chem 2006; 1(4): 400-11.
151. Che Y, Brooks BR, Marshall GR. Development of small molecules designed to modulate protein-protein interactions. J Comput Aided Mol Des 2006; 20(2): 109-30.
152. Pagliaro L, Felding J, Audouze K, et al. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol 2004; 8(4): 442-9.
153. Berg T. Modulation of protein-protein interactions with small organic molecules. Angew Chem Int Ed Engl 2003; 42(22): 2462-81.